PERNIX THERAPEUTICS HLDGS IN
Q2 2017 13F Holders
CUSIP
71426VAK4
Type
Debt
Class
DBCV 4.250% 4/0
Num filings
14
Total reported value, excl. options
$37.1 M
Compare 2017 Q2 to
2020 Q1
2019 Q4
2019 Q3
2019 Q2
2019 Q1
2018 Q4
2018 Q3
2018 Q2
2018 Q1
2017 Q4
2017 Q3
2017 Q1
2016 Q4
2016 Q3
2016 Q2
Manager
Report Date
Value ($000)
Principal
Option Type